Real-World Patient Perspectives on Glipizide and Empagliflozin for Type 2 Diabetes
Keywords:
Empagliflozin,, Glipizide, Diabetes Mellitus, Type II, Jardiance, Jardiance vs. GlipizideAbstract
Background:
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder requiring long-term pharmacological therapy. While Glipizide, a sulfonylurea, remains a common treatment option, newer agents such as Empagliflozin (Jardiance) offer potential additional benefits. Patient-reported experiences may provide valuable insights for optimizing treatment selection.
Methods:
An anonymous, cross-sectional online survey was conducted among adults with T2DM who had prior exposure to both Glipizide and Empagliflozin. Participants answered four questions addressing perceived glycemic control, satisfaction, and treatment preference. Responses were summarized using descriptive statistics.
Results:
A total of 39 patients completed the survey. The majority, 33 participants (85%), reported achieving better glycemic control with Glipizide, whereas 6 (15%) favored Empagliflozin. Satisfaction with Empagliflozin was mixed: 12 patients (31%) were disappointed, 20 (51%) were neutral, and 7 (18%) reported happiness with its use. In comparison, Glipizide was rated more positively, with 5 patients (13%) disappointed, 11 (28%) neutral, and 23 (59%) happy. When asked which medication they would recommend, 18 participants (46%) favored Empagliflozin, while 21 (54%) preferred Glipizide.
Conclusions:
Glipizide was perceived to provide superior glycemic control and greater patient satisfaction compared with Empagliflozin. Nonetheless, nearly half of the participants recommended Empagliflozin despite lower ratings of satisfaction and efficacy. These findings suggest that patient preferences may extend beyond glycemic outcomes alone and highlight the importance of integrating patient-reported experiences into individualized treatment decisions for T2DM.
Downloads
Published
Data Availability Statement
The data supporting the findings of this study are available from the corresponding author upon reasonable request. Individual responses have been anonymized to protect participant confidentiality.
License
Copyright (c) 2025 Journal of Diabesity
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in the Journal of Diabesity (JOD) are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
What this means:
Under the CC BY 4.0 license, authors retain copyright of their work, while allowing others to:
-
Share — Copy and redistribute the material in any medium or format
-
Adapt — Remix, transform, and build upon the material for any purpose, even commercially
Conditions:
Users must provide appropriate attribution to the original author(s) and source, including:
-
The article title
-
Author(s) name(s)
-
Journal name (Journal of Diabesity)
-
DOI or link to the original article
-
An indication if changes were made
There is no restriction on commercial use or derivative works, as long as proper attribution is given.
Full License Text:
https://creativecommons.org/licenses/by/4.0/
✍️ Author Rights:
-
Authors retain copyright and grant JOD the right of first publication.
-
Authors may archive the published version in institutional repositories, personal websites, or other platforms with proper citation.
